Muscle Relaxant Drugs Market Report 2025

The muscle relaxant drugs market size has grown strongly in recent years. It will grow from $4.77 billion in 2024 to $5.16 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to shift in treatment approaches, chronic pain management, pharmaceutical innovation in drug formulations, rise in surgical procedures, expansion in physical rehabilitation practices.

The muscle relaxant drugs market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to multidisciplinary pain management approaches, aging population and chronic conditions, research in targeted therapies, focus on non-pharmacological pain relief, advancements in pain management therapies. Major trends in the forecast period include advancements in side effect profiles, personalized medicine approach, research in alternative therapies, integration of muscle relaxants in pain management protocols, advent of botulinum toxin injections.

The muscle relaxant drugs market is expected to experience growth, driven significantly by the expanding geriatric population. These drugs cater to older adults aged 65 and above, relieving pain and sedating this demographic, which often grapples with musculoskeletal disorders. For instance, as of October 2022, the World Health Organization projected a global surge in the population aged 60 and older, expecting it to reach 1.4 billion by 2022, up from 1 billion in 2020. Projections also indicate that by 2030, roughly one out of every six individuals worldwide will be 60 years or older. This demographic shift is a substantial driver for the muscle relaxant drugs market's growth.

Anticipated growth in the muscle relaxant drugs market is also attributed to the increasing occurrences of sports injuries. These injuries encompass a spectrum of physical traumas arising from engaging in athletic activities, affecting muscles, bones, tendons, ligaments, and joints. Muscle relaxants are integral in managing muscle spasms and injuries incurred during sports activities. For example, according to data released by the National Safety Council in September 2022, reported sports and recreational injuries in the US surged by 20% in 2021 and a subsequent 12% in 2022. Emergency departments treated a total of 3.6 million individuals for injuries related to sports and recreational equipment in 2022. This rise in sports-related injuries is poised to drive the muscle relaxant drugs market.

The muscle relaxant drugs market is witnessing a significant trend characterized by product innovations. Leading market players are actively developing novel drugs tailored for specific medical applications. These innovations include generic versions of muscle relaxant drugs, formulations catering to animal use, and drugs allowing flexible and personalized dosing. Take, for instance, the launch of LYVISPAH by Amneal Pharmaceuticals Inc. in June 2022. This baclofen oral granule product, approved by the US FDA, targets spasticity associated with multiple sclerosis and spinal cord disorders. The granules offer flexible dosing options and accommodate patients experiencing difficulties swallowing pills, presenting a novel alternative in muscle relaxant therapy.

Within the muscle relaxant drugs market, major companies are concentrating on introducing cost-effective alternatives, such as generic muscle relaxant injectables, to gain a competitive edge. These generic injectables replicate the active ingredients found in branded counterparts and are administered via injection. For instance, Lupin Limited launched Rocuronium Bromide Injection in November 2023, following FDA approval. This generic version acts as a substitute for Zemuron Injection by Organon USA Inc., aiding in skeletal muscle relaxation during surgeries or mechanical ventilation. It caters to both inpatients and outpatients and is utilized as an adjunct to general anesthesia.

In June 2023, Corona Remedies completed the acquisition of the muscle relaxant brand Myoril from Sanofi India for INR 234 crore ($31 million). This strategic move fortifies CORONA Remedies' position in the expanding Indian muscle relaxant market. Myoril, with annual sales of INR 38 crore ($5 million) and a growth rate of 6.8%, contributes significantly to Corona Remedies' market presence. Sanofi India, a prominent healthcare and pharmaceutical company specializing in muscle relaxant drugs, facilitated this acquisition.

Major companies operating in the muscle relaxant drugs market are Pfizer Inc., Ipsen Pharma SA, Teijin Limited, Par Pharmaceutical Companies Inc., Orient Phaarma Co. Ltd., Novartis AG, Accord Healthcare Ltd., Amneal Pharmaceuticals LLC, Fresenius Kabi India Pvt. Ltd., Aurobindo Pharma Ltd., Mylan NV, Hikma Pharmaceuticals PLC, Akorn Incorporated, Merck & Co. Inc., Teva Pharmaceuticals Industries Ltd., Lifesciences Limited, Neurana Pharmaceuticals Inc., Dr. Reddy's Laboratories, Lannett Company Inc., Unichem Laboratories, SteriMax Inc., Endo Pharmaceuticals Inc., Abbvie Inc., Merz Pharmaceuticals LLC, Vertical Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Eisai Co. Ltd., Metacel Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Lupin Ltd., Intas Pharmaceuticals Ltd., Alkem Laboratories Ltd.

North America was the largest region in the muscle relaxant drugs market share in 2024. The regions covered in the muscle relaxant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the muscle relaxant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Muscle relaxants are pharmaceuticals utilized to alleviate muscle spasms stemming from neurological conditions, primarily employed to manage muscle pain.

The primary categories of muscle relaxant drugs include facial muscle relaxants, skeletal muscle relaxants, and neuromuscular blocking agents. Facial muscle relaxants specifically target facial spasms and cramps. These medications come in various formulations such as cyclobenzaprine, carisoprodol, chlorzoxazone, metaxalone, methocarbamol, baclofen, tizanidine, orphenadrine, and dantrolene, administered orally, via injection, spray, or ointment. These drugs cater to diverse end-users, encompassing hospitals, home care settings, specialty clinics, and others.

The muscle relaxant drugs market research report is one of a series of new reports that provides muscle relaxant drugs market statistics, including the muscle relaxant drugs industry’s global market size, regional shares, competitors with a muscle relaxant drugs market share, detailed muscle relaxant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the muscle relaxant drugs industry. This muscle relaxant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The muscle relaxant drugs market consists of sales of antispasmodics, benzodiazepines and nonbenzodiazepines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.